These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 19998360)

  • 1. Assessing systemic drug exposure in repeated dose toxicity studies in the case of complete and incomplete sampling.
    Wolfsegger MJ; Jaki T
    Biom J; 2009 Dec; 51(6):1017-29. PubMed ID: 19998360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishing bioequivalence in complete and incomplete data designs using AUCs.
    Jaki T; Wolfsegger MJ; Lawo JP
    J Biopharm Stat; 2010 Jul; 20(4):803-20. PubMed ID: 20496207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Monte Carlo evaluation of five interval estimators for the relative risk in sparse data.
    Lui KJ
    Biom J; 2006 Feb; 48(1):131-43. PubMed ID: 16544818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimation in AB/BA crossover trials with application to bioequivalence studies with incomplete and complete data designs.
    Jaki T; Pallmann P; Wolfsegger MJ
    Stat Med; 2013 Dec; 32(30):5469-83. PubMed ID: 23801551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proportional hazards regression for cancer studies.
    Ghosh D
    Biometrics; 2008 Mar; 64(1):141-8. PubMed ID: 17573863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sparse sampling for assessment of drug exposure in toxicological studies.
    Burtin P; Mentre F; van Bree J; Steimer JL
    Eur J Drug Metab Pharmacokinet; 1996; 21(2):105-11. PubMed ID: 8839683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of lack-of-benefit stopping rules on treatment effect estimates of two-arm multi-stage (TAMS) trials with time to event outcome.
    Choodari-Oskooei B; Parmar MK; Royston P; Bowden J
    Trials; 2013 Jan; 14():23. PubMed ID: 23343147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Applying sample survey methods to clinical trials data.
    LaVange LM; Koch GG; Schwartz TA
    Stat Med; 2001 Sep 15-30; 20(17-18):2609-23. PubMed ID: 11523072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multiclass multivariate group comparison test: Application to drug safety.
    Tohme M; Lengelle R; Freytag V
    Annu Int Conf IEEE Eng Med Biol Soc; 2010; 2010():4711-4. PubMed ID: 21096014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing departure from dose linearity under a repeated measures incomplete block design.
    Cheng B; Chow SC
    Pharm Stat; 2011; 10(4):357-62. PubMed ID: 21104786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of heteroscedasticity between treatment groups on mixed-effects models for repeated measures.
    Gosho M; Maruo K
    Pharm Stat; 2018 Sep; 17(5):578-592. PubMed ID: 29978944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adaptive and repeated cumulative meta-analyses of safety data during a new drug development process.
    Quan H; Ma Y; Zheng Y; Cho M; Lorenzato C; Hecquet C
    Pharm Stat; 2015; 14(3):161-71. PubMed ID: 25612310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variance estimation in clinical studies with interim sample size re-estimation.
    Miller F
    Biometrics; 2005 Jun; 61(2):355-61. PubMed ID: 16011681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The analysis of very small samples of repeated measurements I: an adjusted sandwich estimator.
    Skene SS; Kenward MG
    Stat Med; 2010 Nov; 29(27):2825-37. PubMed ID: 20839367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Epidemiological and statistical methods of risk assessment].
    Behrens T; Pigeot I; Ahrens W
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2009 Dec; 52(12):1151-60. PubMed ID: 20012566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of bias-corrected covariance estimators for MMRM analysis in longitudinal data with dropouts.
    Gosho M; Hirakawa A; Noma H; Maruo K; Sato Y
    Stat Methods Med Res; 2017 Oct; 26(5):2389-2406. PubMed ID: 26265765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of agile designs in first-in-human (FIH) trials--a simulation study.
    Perlstein I; Bolognese JA; Krishna R; Wagner JA
    AAPS J; 2009 Dec; 11(4):653-63. PubMed ID: 19763840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conditional estimation using prior information in 2-stage group sequential designs assuming asymptotic normality when the trial terminated early.
    Shimura M; Maruo K; Gosho M
    Pharm Stat; 2018 Sep; 17(5):400-413. PubMed ID: 29687592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exact tests using two correlated binomial variables in contemporary cancer clinical trials.
    Yu J; Kepner JL; Iyer R
    Biom J; 2009 Dec; 51(6):899-914. PubMed ID: 20014199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Confidence intervals for ratios of AUCs in the case of serial sampling: a comparison of seven methods.
    Jaki T; Wolfsegger MJ; Ploner M
    Pharm Stat; 2009; 8(1):12-24. PubMed ID: 18407562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.